You will receive 29 continuing education credits from the Kassenzahnärztliche Vereinigung Bayerns (KZVB) for participation!
Place: Practice clinic Dr. Johann Lechner, Grünwalder Straße 10a, Munich Cost: 828,57 € incl. 19% VAT per person / 633,61 € for co-workers from the same practice (Price incl. 19% VAT) incl. coffee, tea and softdrinks Speaker: Dr. Johann Lechner PhD-UCN
Sign up now for the CaviTAU® Hands-on-Training Practice Clinic Dr. Dr. Johann Lechner
By working independently, you will find out how easy it is to identify FDOKs (NICOs) with the new CaviTAU® device! In this training you will get more practice and will be able to train with the CaviTAU®
Topics of the training
How to generate reliable data & create correct ultrasound evaluation for your diagnostics using the CaviTAU® device
create reliable interpretations of the test results that correctly read, understand & evaluate CaviTAU® images
Learn how to recognize FDOK’s / NICO’s quickly and easily
Get in touch with the simple & correct handling & operation of the CaviTAU® device
Become more secure in your dental diagnostics
Workshop and presentation by Dr. Dr. (PhD-UCN) Johann Lechner on the topic “Interpretations of maxillo-mandibular osteoimmunology
Upcoming dates for the hands-on training 2021
Description of the training
The workshop is aimed at all those who would like to “lend a hand” themselves and experience the new CaviTAU® device in practical use. Don’t miss this opportunity in a limited group of participants to test the CaviTAU® device and convince yourself of the simple and fast operation.
Practice Clinic Dr. Johann Lechner, Grünwalder Strasse 10a, Munich
399,00 € including 19% VAT. per person
Dr. Dr. (PhD-UCN) Johann Lechner
Advanced training points (KZVB)
You will receive 8 advanced training points from the Bavarian Dental Association (KZVB) for participating! You can download our hygiene concept for this event here: Hygiene Concept OP Seminar 2021
Visualization of the cavity-forming osteolyses in the jawbone with sonography
What does this Band IV show on 304 pages?
Band IV describes radiation-free imaging for maxillo-mandibular osteoimmunology and with CaviTAU® measuring images, the expected bone marrow defects in the jaw are finally objectively visible and comprehensible.
With more than 200 multi-colored images for the interpretation of CaviTAU® ultrasound measurements of bone density in the jaw
Over 560 literature qoutes to the scientific background
After Band I 2011, Band II 2015 Band III 2019 in the series “Cavity-forming osteolyses of the jawbone” now see Band IV in 2020.
These four books by the author Dr.Dr. (PhD-UCN) J. Lechner with the collaboration of Prof. JE. Bouquot and Dr. V. von Baehr with a total of more than 800 colored illustrations and over 1,500 literature qoutes establish the new therapy and research branch of a “Maxillo-Mandibular Osteoimmunology” on 1,100 pages.
Extending far beyond any X-ray diagnostics, Band IV describes in detail the newly developed ultrasound device CaviTAU® in Germany for visualizing the cavity-forming osteolyses in the jawbone.
We are pleased to inform you that we have overcome all necessary admission hurdles by the end of the year.
Since January of this year we have been in the final development phase of the new CaviTAU® device. The last few weeks and months have been marked by the requirements of EU directives and other obligations from the Medical Law. By the end of the year, all official requirements have now been met. We are pleased to send you an image of the software interface.
What will happen in January 2020?
At the same time we can send you further, following information regarding the further steps to the CaviTAU® device:
CaviTAU® production starts:
In the meantime, the fully functioning CaviTAU® device has been successfully tested in the practice clinic Dr. Lechner over a long BETA test. We can now proudly say that the device works and already exceeds all of our internal expectations. Series production of the device has started, so you can expect to buy the first devices in the first quarter of 2020.
CaviTAU® web shop: An online shop is expected to be available in February 2020 to purchase the CaviTAU® device. In the future, you will then have the opportunity to easily obtain any consumables and / or device support via the online shop.
Official marketing start:
Since we are now in the final stages of the market launch, we will inform you in January 2020 about all other concrete points, such as
Exact start of sales
Possible product variants and accessories
Training dates, etc …
We are currently planning so-called “devices / demonstrations” at events (e.g. DEGUZ annual meeting or GZM annual meeting). As soon as the exact dates have been set for these demo days, we will announce these “DEMO dates” on our CaviTAU® website stage.cavitau.de or inform you trough out our CaviTAU® newsletter.
ICOSIM special offer
We can place another happy message for all ICOSIM members: All ICOSIM members will be considered for the purchase of the devices.
For anyone who is not yet a member, but still wants to become a member: Register here as an ICOSIM member.
We are pleased to inform you, that we are in the final stages regarding the relaunch phase of the CaviTAU® device. The device is currently being used in in the practice clinic Dr.Lechner and already exceeds our internal expectations. In addition, we are currently planning so-called “device / demonstrations” at events. (e.g. the DEGUZ annual meeting or at a later date. The official launch is planned for the end of summer this year, an official date for the market launch is yet to be announced. Unfortunately, due to the ongoing approval process, we can not yet give any information about the selling price. For a presale right you can register here as an ICOSIM member until 30.06.2019 for free. All newsletter subscribers will be the first ones to know about the final launch date and launch price.
After the publication of Volume I in 2011 and Volume II in 2015, Volume III, on the cavity-forming osteolyses of the jawbone with their oral and systemic manis fixations, will be published in 2019 by Dr.Dr.(PhDUCN) J. Lechner, Prof. JE. Bouquot und Dr. V. von Baehr.
with more than 600 colored illustrations and over 1,000 literature citations on more than 800 pages explain and justify the new therapy and research branch of a „Maxillo-Mandibular Osteoimmunology”.
Promotion of the CaviTAU® project by an initiative of the Bavarian Ministry of Economic Affairs
Our developments on CaviTAU® are funded by the state, as the decision makers of the Bavarian Ministry of Economic Affairs (Bayern-Innovativ) have recognized the importance of our TAU ultrasound equipment in dental diagnostics. The future-oriented significance of the treatment options for autoimmune diseases opened up by CaviTAU® is thereby strengthened.
So far, as a nice recognition, we have been awarded four innovation vouchers for the development of the CavTAU® device and its validation on patients.
a) FDOJ (fatty-degenerative Osteolysis/Osteonecrosis of the Jawbone) is characterized by the absence of the usual clinical parameters of local tooth and jaw pain, with the exception of the more diffuse atypical facial pain (FDOJ is in these pain cases called “NICO”) and the radiographic inconspicuousness. (Literatur: Lechner, J. Validation of dental X-ray by cytokine RANTES – comparison of X-ray findings with cytokine overexpression in jawbone. Clinical, Cosmetic and Investigational Dentistry 2014:6 71–79..: https://www.dovepress.com/articles.php?article_id=18049&l=bBexMykzNGYEHIPfWZ1MT6xu198194
b) FDOJ is morphologically and macroscopically characterized by a fatty-degenerative dissolution of the spongiosal jawbone with conspicuous structural softening and osteolysis. (Literature: Lechner J, von Baehr V. Chemokine RANTES/CCL5 as an unknown link between wound healing in the jawbone and systemic disease: is prediction and tailored treatments in the horizon? EPMA Journal.2015, 6:10. DOI: 10.1186/s13167-015-0032-4
d) Our research indicates that overactivated signal transduction cascades may be specific to RANTES / CCL5 in radiologically unrecognized FDOJ sites in association with RANTES / CCL5 effects in complex chronic diseases. For the first time, we present a scientifically validated explanatory model of the so-called “disturbance field effect” from jawbone area. (Literature: Lechner J, von Baehr V. Journal of Breast Cancer: Basic and Clinical Research: „Hyperactivated Signaling Pathways of Chemokine RANTES/CCL5 in Osteopathies of Jawbone in Breast Cancer Patients—Case Report and Research”.
However, in a literature review, the modern knowledge gained on the pathophysiological role of the chemokine RANTES / CCL5 in systemic diseases contrasts with minimal hits in relation to RANTES / CCL5 from FDOK areas: Are keywords in the search engine GoogleScholar for 22 diseases and their connection to RANTES / CCL5 “Allergy AND RANTES CCL5” hits 9,500, “Cancer Reviews AND RANTES CCL5” 9,410, “Rheumatoid Arthritis AND RANTES CCL5” 7,310, “Colon Cancer” 6,330, ” Breast Cancer, etc. “to 5,150,” Multiple Sclerosis, etc. “to 5,140,” Pancreas Carcinoma, etc. “to 4,180,” Melanoma, etc. “to 3,940,” Breast Cancer Metastasis, etc. “to 3,750,” Prostate Cancer, etc. “at 3,480,” Depression, etc. “at 2,440,” Alzheimer Disease, etc. “at 2,190,” Thyroid, etc. “at 1,940,” Thyroid, etc. “at 1,940,” Hodgkin, etc. ” “Au f 1,770, “Non-Hodgkin, etc.” to 1,750, “Parkinson’s Disease, etc.” to 1,370, “Periodontitis, etc.” to 942, “Opioid Receptor, etc.” to 862, “ALS, etc.” on 556, on “Lichen Planus, etc.” on 356, on “Trigeminal Neuralgia, etc.” on 227, on “Jawbone, etc.” on 32, of which 14 are their own publications.
Enoral measurement of bone density with the new CaviTAU® device by trans-alveolar ultrasound (TAU)®
We therefore present you this pilot measurement with the CaviTAU® prototype because the measurement results are confirmed clinically: A 34-year-old female patient has been suffering from atypical facial pain for 2 years, starting from the upper left jawbone area in severely repeating pain attacks. After the first “NICO” surgery by removal of the fatty degenerative jawbone (FDOJ) at area 25/26, the neuralgic facial pain disappears completely. Here we compare in several pictures the difference in bone density by means of CaviTAU® imaging of successfully restored FDOJ / “NICO” (area 25 in Figure 1) with jawbone areas still loaded with FDOJ (area 15 in Figure 3) in the same patient.
CaviTAU® ultrasound imaging of an still existing FDOJ in area 15. The direction of the measurement path runs from occlusal to apical or from caudal to cranial:
The interpretation of CaviTAU® imaging in non-rehabilitated jawbone area 15; the attenuation of the dental plastic bridge at 15 has not yet been fully investigated.
The CaviTAU® imaging at area 25 five months after successful rehabilitation of the trigeminal neuralgia; patient is now completely free of pain. X-ray is preoperative uptake. The direction of the measurement path runs from occlusal to apical or from caudal to cranial.
The interpretation of ultrasound imaging in the restored jawbone in area 25 (no FDOJ/“NICO”).
The significance and clinical need for a TAU analysis in cases of chronic atypical facial pain or trigeminal neuralgia and the inadequate presentation of fatty-degenerative osteolysis in the jawbone FDOJ / “NICO” by X-rays is documented in our own scientific publications:
Lechner J, von Baehr V. Peripheral Neuropathic Facial/Trigeminal Pain and RANTES/CCL5 in Jawbone Cavitation, Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 582520, 9 pages, 2015. doi:10.1155/2015/582520https://www.hindawi.com/journals/ecam/2015/582520/ Lechner, J. Validation of dental X-ray by cytokine RANTES – comparison of X-ray findings with cytokine overexpression in jawbone. Clinical, Cosmetic and Investigational Dentistry 2014:6 71–79https://www.dovepress.com/articles.php?article_id=18049 https://www.ncbi.nlm.nih.gov/pubmed/25170282 All publications by Hans Lechner and co-authors can be found on the Science Platform Researchgate https://www.researchgate.net/profile/Johann_Lechner/publications